Abstract: The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.

Abstract: Biocompatible metallic medical devices having silanized surfaces coupled to nucleophile residues that release sustained, therapeutic amounts of nitric oxide to specific sites within a mammalian body are provided. Additionally, the biocompatible metallic medical devices can also be provided with anti-thrombogenic, lubricious coatings that release sustained, therapeutic amounts of nitric oxide. Moreover, the silanized metallic devices are surprisingly durable when exposed to harsh chemical methods often needed to bind nitric oxide-releasing functional groups to nucleophile residues. Furthermore, methods are provided for producing stable, silanized, sustained nitric oxide-releasing metallic medical devices.

Abstract: Biocompatible polymeric materials capable of providing in situ release of nitric oxide (NO) included diazeniumdiolated fumed silica as a filler in a multilayer polymer structure to release NO upon contact with water (blood). The blood-contacting polymer surface is preferably multi-layered so that the NO-releasing layer, containing the diazeniumdiolated fumed silica, is shielded from blood contact by one or more top (or base) coats. When in contact with blood, the NO released at the surface of the polymer prevents platelet activation and adhesion to the surface, thereby reducing platelet consumption, risk of thrombus formation and other clinical complications associated with interactions between blood and foreign materials.

Abstract: The present invention relates to a crosslinked optically active three-dimensional polymer network consisting of at least one homochiral unit of at least one first selector and of at least one homochiral unit of at least one second selector of structure different from the first selector and optionally of at least one homochiral unit of at least one third selector of structure different from the first and from the second selector, the homochiral unit(s) of the first selector containing one polymerizable functional group, the homochiral unit(s) of the third selector containing at least one polymerizable functional group and the homochiral unit(s) of the second selector containing at least two polymerizable or crosslinkable functional groups, the homochiral units being chemically linked to one another, to a method for preparing thereof and methods using thereof.

Abstract: Spermine:peptide-based surfactant compounds are disclosed. The compounds are based on a spermine backbone with peptide groups and optionally hydrocarbyl groups linked thereto. Uses of the spermine:peptide-based surfactant compounds and methods for their production are also disclosed.

Abstract: Drug-oligomer conjugates and pharmaceutical compositions prepared therefrom. Methods of making and using the drug-oligomer conjugates and pharmaceutical compositions.

Abstract: Polylactic acid derivatives capable of forming micelles in an aqueous solution with a pH of 4 or above, having one terminal carboxyl group. The polylactic acid derivatives may be applied as a drug delivery system in various forms since poorly water soluble drugs can be entrapped inside the micelles.

Abstract: Biocidal compositions formed by metathesis of either monomeric or polymeric bioactive cations with either monomeric or polymeric bioactive anions to from an essentially water insoluble complexes.

Abstract: Biocidal compositions formed by metathesis or acid-base reactions by combing either monomeric or polymeric bioactive cations with either bioactive monomeric or polymeric anions or by the reaction of a free base with an organic compound capable of donating a proton to the free base to form an essentially water insoluble complexes. Said complexes can be solubilized to yield water-soluble emulsions or microemulsions. These novel and unique compositions are effective wood preservative, which are totally organic substances not having any toxic heavy metal ions present.

Abstract: Polyazo compounds, which include low molecular weight drugs having a carboxylic acid group and an amine, thiol, alcohol or phenol group within their structure, formed into polymeric drug delivery systems are provided. Also provided are methods of producing polymeric drug delivery systems having these polyazo compounds as well as methods of administering low molecular weight drugs to a host via the polymeric drug delivery systems.

Abstract: The present invention relates to a polymeric drug conjugate with one or more biologically active agents conjugated via an enzymatically cleavable linker to either a regular repeating linear unit comprising a water soluble polymer segment and a multifunctional chemical moiety, or a branched polymer comprising two or more water soluble polymer segments each bound to a common multifunctional chemical moiety, as well as to methods of making such conjugates. The present invention is also directed to pharmaceutical compositions comprising such conjugates and to the use of such conjugates to treat pathological conditions.

Abstract: A stimuli-responsive polymer derivative utilizing keto-enol tautomerization. Also disclosed are a simple process for producing an N-acyl(meth)acrylamide derivative which can be used as a monomer for the stimuli-responsive polymer, a process for the production of an intermediate thereof, and an intermediate thus produced.

Abstract: A method of treating insect bites includes applying a polymerizable monomer adhesive composition to an area of skin afflicted with an insect bite, optionally with at least one of an additional active agent, and allowing the polymerizable monomer composition to polymerize to form a polymer film over the area of skin.

Abstract: The present invention relates to novel compositions for disinfecting and sealing a substrate, while also providing the surface with long-term fungicidal protection. Due to this unique and advantageous combination of capabilities, the composition finds particular utility in the construction industry, where it may advantageously be employed to treat a wide variety of construction articles.

Abstract: Therapeutic polymers containing hydroxamate group that binds and thus inhibits zinc containing enzymes such as matrix metalloproteinases. The implantation of such material inhibits remodeling in its vicinity.

Abstract: A conjugate comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-, hydroxy- or carboxyl-containing ligand is described. The resulting conjugate is capable of releasing the parent amine, hydroxy, or carboxyl-containing compound via thiol-mediated cleavage. The system allows for delivery of various amino-, hydroxy-, or carboxy-containing drugs in the form of their thiolytically cleavable macromolecular conjugates.

Abstract: Anthrax bio-terrorism is a poor man's nuclear bomb with devastating effects on the freedom and economy of any nation. No nation is immune. Urgently, there is a need for life saving technology that can be readily available and deployed in real time. Polystyrene sulfonate is the answer. It is life saving and will help in the development of next generation superior vaccines.

Abstract: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.

Abstract: The use of a composition of one or more aminoalcohol buffers in combination with one or more antimicrobial agents to disinfect contact lenses and preserve ophthalmic lens compositions is described. Ophthalmic lens solutions containing compositions of one or more aminoalcohol buffers in combination with one or more antimicrobial agents and methods of making and using the same are also described.

Abstract: Dendritic polymer conjugates which are useful drug delivery systems for carrying platinum containing anti-tumor agents to malignant tumors are prepared by obtaining a dendritic polymer having functional groups which are accessible to a platinum containing compound capable of interacting with the functional groups, contacting the dendritic polymer with the platinum containing compound, and reacting the dendritic polymer with the platinum containing compound. The dendritic polymer platinates may be administered intravenously, orally, parentally, subcutaneously or topically to an animal having a malignant tumor in an amount which is effective to inhibit growth of the malignant tumor. The dendritic polymer platinates exhibit high drug efficiency, high drug carrying capacity, good water solubility, good stability on storage, reduced toxicity, and improved anti-tumor activity in vivo.

Abstract: An adhesive including a mixture of isocyanate capped molecules formed by reacting multi-isocyanate functional molecules with multi-functional precursor molecules including terminal functional groups selected from the group consisting of a hydroxyl group, a primary amino group and a secondary amino group. Preferably, the functional groups are hydroxyl groups. The multi-functional precursor compounds are biocompatible. Multi-aminc functional precursors of the multi-isocyanate functional molecules are also biocompatible. As discussed, above, the mixture of molecules preferably has an average isocyanate functionality of at least 2.1 and, more preferably, has an average isocyanate functionality of at least 2.5. As also described above, the mixture of molecules preferably has a viscosity in the range of approximately 1 to approximately 100 centipoise. The mixture of molecules forms a crosslinked polymer network upon contact with the organic tissue in the presence of water.

Abstract: The present invention provides polysubstituted polycarboxylic phosphoamide biopolymers (PPPBs) comprising polysaccharides and glycopolypeptides attached to a phospho-citrate backbone. Phosphorylation of the biopolymers yields phosphorylated polysubstituted polycarboxylic phosphoamide biopolymers (pPPPBs) which can be used as inflammatory response modulators, immunomodulators and/or biological response modifiers. Methods for producing the PPPBs in yeast subjected to multiple chemical stressors, and uses of compositions derived therefrom, are provided.

Abstract: A process for purification which permits satisfactory removal of impurities from a block copolymer consisting essentially of polyethylene glycols and poly(acidic amino acid) and is suitable for the production of a polymeric carrier having a pharmaceutically acceptable purity; a process for producing such a polymeric carrier; a block copolymer reduced in impurity content; a polymeric carrier as described above; pharmaceutical preparations in polymeric form, produced by the use of the carrier; and a method of subjecting polyethylene glycols and poly(acidic amino acids)—which are impurities contained in the block copolymer—to treatment with either an ion-exchange resin or a partition/absorption resin and then determining the quantities of them with a gel filtration column.

Abstract: One aspect of the present invention relates to methods and compositions for attenuating xenograft rejection by administering, to an animal receiving the xenograft, an amount of a polymer-derivatized xenoantigen (hereinafter “xenopolymer”) effective for inhibiting or lessening the severity of hyperacute rejection response (HAR), or other immunological response to the graft, that is dependent on the presence of the xenoantigen on the grafted tissues or cells. In certain embodiments, the xenopolymer is administered in an amount sufficient to neutralize host antibodies (“xenoreactive antibodies” or “XNA”) immunoreactive with the xenoantigen. The xenopolymer may additionally, or alternatively, be used as a tolerogen (or anergen) for the xenoantigen, e.g., able to suppress, to some degree, the production/secretion of XNAs by the immune system of the host.

Abstract: The present invention relates to site-specific conjugation of synthetic particles to proteins.

Abstract: A biocompatible polymer constituted by a sequence of identical or different components of the general formula (I): AaXxYy, in which A represents a monomer, X represents a carboxyl group fixed on a monomer A, Y represents a sulfate or sulfonate group fixed on a monomer A; a represents the number of monomers A, x represents the substitution rate of the set of monomers A by the groups X, y represents the substitution rate of the set of monomers A by the groups Y. The invention also pertains to the pharmaceutical or diagnostic compositions containing at least one polymer of general formula (I).

Abstract: Amine polymers, particularly aliphatic amine polymers, are useful in the treatment and prevention of bone disease and in methods for promoting bone formation. Sevelemer, polyallylamine crosslinked with epichlorohydrin, which is sold under the tradename Renagel®, is the preferred polymer used in the invention.

Abstract: The present invention is directed to compositions comprising polymeric tertiary amines of urethane esters and salts thereof. The compositions are generally derived from linear or branched chain compounds of synthetic or natural origin, preferably from trialkalnolamines that have been esterified with organic acids including long chain fatty acids and reacted with diisocyanate compounds to form urethane adducts. These adducts are in turn polymerized with organic acids to form polymeric urethane ester tertiary amine salts. The compositions of the present invention may be incorporated into personal care formulations such as cosmetics, toiletries and shampoos and into detergents to improve or modify at least two of the characteristics of such formulations.

Abstract: The present invention relates to the discovery that certain anionic polymers have useful antibacterial activity.

Abstract: A sterilizing disinfectant and an antimicrobial agent comprising a cationic polymer represented by general formula [1] and an antimicrobial material using a cationic polymer represented by general formula [1].

Abstract: Improved molecularly imprinted polymers (MIPs) with both higher and more specific binding capacity for particular bile acids and/or salts, including the synthesis of such MIPs, the compounds themselves, and specific applications thereof. As an example of a particularly preferred specific application of these compounds, the present invention encompasses the use of the MIPs as sequestrants in the gastrointestinal tract, particularly in order to bind and therefore remove toxins from the gastrointestinal tract. In addition, the present invention is also useful for treatment of various diseases which are related to, and/or characterized by, an effect of bile acids and salts, such as atherosclerosis, liver disease and various diseases of the gastrointestinal tract. The MIP compounds of the present invention are also useful for combination therapy with other medications and for diagnosis and monitoring of diseases.

Abstract: Extremely hydrophobic nitric oxide (NO) releasing polymers are disclosed. The extremely hydrophobic NO-releasing polymers provided are extensively cross-linked polyamine-derivatized divinylbenzene diazeniumdiolates. These polymers can be loaded with extremely high NO levels and designed to release NO in manners than mimic natural biological systems. The NO-releasing extremely hydrophobic polymers provided can maintain a sustained NO release for periods exceeding nine months. Also provided are related medical devices made using these NO-releasing extremely hydrophobic polymers.

Abstract: The present invention relates to purified platinum complexes in which platinum is coordinated to form a single N,O- or O,O-chelate of an amidomalonate. The chelates, and pharmaceutically acceptable formulations thereof, are useful for the treatment of cancer. The platinum chelates may additionally be linked to one or more functional groups which increases water solubility and/or assists in tumor targeting of the chelate. Examples of tumor targeting moieties include polymers, in which one or more platinum chelates are attached to the polymer backbone via linkers capable of being cleaved in the body, and molecules with a high affinity for receptors which are concentrated or upregulated in tumor tissue and/or the tumor vasculature.

Abstract: An aqueous artificial tear/rewetting drop solution is described. The solution may be utilized as both an artificial tear for persons wearing contact lenses and as a contact lens rewetting drop. The solution is based on the use of a citric acid/sodium citrate buffer system to prevent binding or other complexation between cationic antimicrobial preservatives and soft contact lenses, thereby making it possible to apply the solution directly to contact lenses while the lenses are being worn.

Abstract: This invention relates to the use of at least one water-soluble polymer, obtained by copolymerization of at least one monomer (a) with ethylenic unsaturation having a group capable of being protonated in the application medium with at least one monomer with ethylenic unsaturation (b) which is copolymerizable with (a) carrying a functional group with an acidic nature capable of being negatively ionized in the application medium; and optionally at least one monomer with ethylenic unsaturation (c) with a neutral charge, preferably carrying one or more hydrophilic groups, which is copolymerizable with (a) and (b); for improving the biocidal effectiveness of biocidal compositions comprising a cationic biocidal compound.

Abstract: An emulsion composition for the topical application comprising: (a) A polymeric oily phase; (b) A polymeric emulsifier; (c) An aqueous phase; (d) A polymeric antimicrobial and optionally one or more components selected from polymeric film formers, inorganic and polymeric stabilizers, other inorganic or polymeric excipients and mixtures thereof.

Abstract: Provided is a cosmetic or a dermatological composition comprising as an active ingredient, a specific acryl base copolymer having phosphorylcholine as a side chain or a pendant group. Such active ingredient can inhibit or repair skin damages by strengthening the expression of a &bgr;-glucocerebrosidase gene.

Abstract: A method for treating pathogenic toxins in a mammal, such as a human, comprising treating the mammal with a therapeutically effective amount of a polymer comprising a cationic group attached to the polymer backbone. The polymer can be a homopolymer or a copolymer. In one embodiment, the polymer is a copolymer comprising a monomer having a pendant ammonium group and a hydrophobic monomer.

Abstract: Embolic compositions comprising macromers having a backbone comprising a polymeric backbone comprising units with a 1,2-diol or 1,3-diol structure, such as polyvinyl alcohol, and pendant chains bearing crosslinkable groups and, optionally, other modifiers. When crosslinked, the macromers form hydrogels having many properties advantageous for use as embolic agents to block and fill lumens and spaces. The embolic compositions can be used as liquid embolic agents and crosslinked in situ or as preformed embolic articles, such as microspheres.

Abstract: Compositions comprising macromers having a backbone comprising units having a 1,2-diol and/or 1,3-diol structure for tissue bulking and coating. Such polymers include poly(vinyl alcohol) (PVA) and hydrolyzed copolymers of vinyl acetate, for example, copolymers with vinyl chloride, N-vinylpyrrolidone, etc. The backbone polymer contains pendant chains bearing crosslinkable groups and, optionally, other modifiers. When crosslinked, the macromers form hydrogels having many properties advantageous for use as agents to bulk and coat tissue.

Abstract: A complex comprising cisplatin and a poly(ethylene glycol)/poly(glutamic acid) block copolymer, wherein the cisplatin is enclosed in the copolymer through ligand displacement in which a carboxyl anion of the copolymer is replaced with a chlorine ion of the cisplatin. This complex can give a medicine reduced in toxicity and usable by a new method of administration.

Abstract: The invention relates to compounds of the general formula (I), as defined, and to pharmaceutical compositions containing them.

Abstract: The invention relates to compounds of the general formula (I) 1

Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of preparation.

Abstract: A biocompatible monomer composition includes: (A) at least one monomer, which forms a medically acceptable polymer; (B) at least one plasticizing agent present in the composition in an amount of from 0.5 wt. % to 15 wt. % of the composition; and (C) at least one acidic stabilizing agent having a pKa ionization constant of from about 1 to about 7. The composition can be applied to a variety of materials and is particularly suitable as in vivo tissue adhesive. A method of joining together in vivo two surfaces, e.g.

Abstract: A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of a non-absorbable amine polymers characterized by a repeat unit having the formula: 1

Abstract: A prion-physiological structure and associated method of formation. A provided abnormal prion has a transforming power over a normal prion to convert the abnornal prion into defective prion that mimics the abnormal prion. A linker molecule is then bonded to the abnormal prion, wherein a polymer that is covalently attached to the linker molecule facilitates formation of a polymerized abnormal prion that does not have the transforming power over the normal prion.

Abstract: Extremely hydrophobic nitric oxide (NO) releasing polymers are disclosed. The extremely hydrophobic NO-releasing polymers provided are extensively cross-linked polyamine-derivatized divinylbenzene diazeniumdiolates. These polymers can be loaded with extremely high NO levels and designed to release NO in manners than mimic natural biological systems. The NO-releasing extremely hydrophobic polymers provided can maintain a sustained NO release for periods exceeding nine months. Also provided are related medical devices made using these NO-releasing extremely hydrophobic polymers.

Abstract: The present invention relates to an antibacterial aqueous solution comprising a complex of an anionic surfactant, a polycationic antibacterial agent and water.

Abstract: The present invention provides fat-binding polymers, which comprise dialkanolamine, dialkanolammonium, aminoalkylpolyol, and ammoniumalkylpolyol pendant groups for subjects in need of fat removal from the gastrointestinal tract, particularly subjects suffering from steatorrhea and/or experiencing side effects from lipase inhibitors. Patients being administered with lipase inhibitors are typically being treated for Type II Diabetes, streatorrhea, and hypertriglyceridemia. The fat binding polymers of this invention are also suitable for use with obese subjects.